Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans.
The susceptibilities of 87 periodontitis-associated strains of Actinobacillus actinomycetemcomitans to clarithromycin and erythromycin were determined by standard methodology recommended for Haemophilus influenzae. For clarithromycin the MIC at which 90% of the isolates were inhibited was </=2.0 microg/ml and the minimal bactericidal concentration at which 90% of the strains were killed was </=4.0 microg/ml, suggesting that it would be a candidate for therapeutic trials in patients with periodontitis.
Piccolomini
R
R
Department of Biomedical Sciences, Clinical Microbiology Laboratory, "G. D'Annunzio" University, I-66100 Chieti, Italy. r.piccolomini@dsb.unich.it
Catamo
G
G
Di Bonaventura
G
G
D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010518:Periodontitis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D004917:Erythromycin; D017291:Clarithromycin